To determine whether and where universal neonatal screening for hemoglobinopathies, chiefly sickle-cell disease, could be performed at socially acceptable costs.
We made projections of the cost-effectiveness of nonuniversal and universal sickle-cell disease screening throughout the United States.
We then compared the cost-effectiveness of universal sickle-cell disease screening with that of universal phenylketonuria screening.
Finally, we asked if « high-cost » states, that is, those in which the cost of finding a case of sickle-cell disease exceeded one half the cost of finding a case of phenylketonuria, could enhance their cost-effectiveness by joining demographically complementary states in screening cooperatives.
Mots-clés Pascal : Hémoglobinopathie, Economie santé, Dépistage, Coût, Nouveau né, Homme, Etats Unis, Amérique du Nord, Amérique, Hémopathie, Anémie hémolytique
Mots-clés Pascal anglais : Hemoglobinopathy, Health economy, Medical screening, Costs, Newborn, Human, United States, North America, America, Hemopathy, Hemolytic anemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0487621
Code Inist : 002B20G01. Création : 199501.